GlassScriptPhysician profile
Dale A Swims
NPI 1265748008
$5,361.83
in general payments reported to CMS, 2019-2025
46 companies · $931 in 2025
The $931 reported for 2025 was more than what 84% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $488 · 2020: $37.98 · 2021: $1,011 · 2022: $805 · 2023: $1,065 · 2024: $1,023 · 2025: $931.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,932 · Education: $87.49.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,932.17 |
| Education | $87.49 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $718.11 | 2019-2025 | Rybelsus, Ozempic, Wegovy |
| Abbvie INC. | $655.81 | 2021-2025 | Viberzi, Linzess, Creon |
| Bayer Healthcare Pharmaceuticals INC. | $346.51 | 2021-2024 | |
| Janssen Pharmaceuticals, INC | $336.56 | 2019-2022 | |
| Lilly USA, LLC | $335.19 | 2021-2025 | Mounjaro, Jardiance, Kisunla |
| Pfizer INC. | $303.86 | 2019-2024 | |
| Novartis Pharmaceuticals Corporation | $278.68 | 2019-2024 | |
| Dexcom, INC. | $186.82 | 2021-2023 | Dexcom G6 Transmitter |
| Amgen INC. | $186.29 | 2019-2024 | Repatha, Otezla, Krystexxa |
| Teva Pharmaceuticals USA, INC. | $166.55 | 2025 | Austedo Xr |
| Gilead Sciences, INC. | $150.25 | 2019-2025 | |
| Glaxosmithkline, LLC. | $132.25 | 2021-2025 | Arexvy, Trelegy Ellipta, Shingrix |
| Lundbeck LLC | $130.56 | 2023-2025 | Rexulti |
| Viiv Healthcare Company | $123.03 | 2024-2025 | Apretude |
| Merck Sharp & Dohme LLC | $114.95 | 2019-2025 | Belsomra, Steglatro, Capvaxive |
Show all 46 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Dale Swims listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.